$416.20 Million in Sales Expected for West Pharmaceutical Services Inc. (WST) This Quarter

Wall Street analysts predict that West Pharmaceutical Services Inc. (NYSE:WST) will post sales of $416.20 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for West Pharmaceutical Services’ earnings, with the highest sales estimate coming in at $420.00 million and the lowest estimate coming in at $411.50 million. West Pharmaceutical Services posted sales of $382.30 million during the same quarter last year, which suggests a positive year over year growth rate of 8.9%. The firm is scheduled to announce its next quarterly earnings report before the market opens on Thursday, February 15th.

According to Zacks, analysts expect that West Pharmaceutical Services will report full year sales of $416.20 million for the current year. For the next year, analysts expect that the firm will post sales of $1.73 billion per share, with estimates ranging from $1.71 billion to $1.74 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow West Pharmaceutical Services.

Several equities research analysts have recently commented on the company. Zacks Investment Research raised West Pharmaceutical Services from a “sell” rating to a “hold” rating in a report on Friday, January 26th. Wells Fargo & Co increased their price objective on West Pharmaceutical Services from $105.00 to $112.00 and gave the company an “outperform” rating in a report on Friday, October 27th. Goldman Sachs Group assumed coverage on West Pharmaceutical Services in a report on Wednesday, January 24th. They issued a “neutral” rating and a $110.00 price objective for the company. Finally, Bank of America downgraded West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 price objective for the company. in a report on Tuesday, October 17th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $108.17.

In other news, CFO William J. Federici sold 21,000 shares of the stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $99.01, for a total value of $2,079,210.00. Following the completion of the sale, the chief financial officer now owns 190,493 shares of the company’s stock, valued at approximately $18,860,711.93. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 1.90% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Citigroup Inc. raised its stake in West Pharmaceutical Services by 95.1% in the 2nd quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock valued at $148,000 after acquiring an additional 765 shares during the period. Grandfield & Dodd LLC bought a new stake in West Pharmaceutical Services in the 3rd quarter valued at $201,000. Alps Advisors Inc. bought a new stake in West Pharmaceutical Services in the 4th quarter valued at $206,000. Nomura Holdings Inc. bought a new stake in West Pharmaceutical Services in the 2nd quarter valued at $201,000. Finally, Private Advisor Group LLC bought a new stake in West Pharmaceutical Services in the 3rd quarter valued at $202,000. Institutional investors and hedge funds own 92.69% of the company’s stock.

Shares of West Pharmaceutical Services (WST) opened at $90.42 on Friday. The company has a market capitalization of $6,995.37, a P/E ratio of 40.61, a PEG ratio of 2.00 and a beta of 1.04. The company has a quick ratio of 1.87, a current ratio of 2.59 and a debt-to-equity ratio of 0.15. West Pharmaceutical Services has a twelve month low of $77.97 and a twelve month high of $103.36.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Thursday, January 18th were issued a $0.14 dividend. This represents a $0.56 annualized dividend and a dividend yield of 0.62%. The ex-dividend date of this dividend was Wednesday, January 17th. West Pharmaceutical Services’s payout ratio is presently 22.31%.

WARNING: This piece was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/09/416-20-million-in-sales-expected-for-west-pharmaceutical-services-inc-wst-this-quarter.html.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply